Drug | ATC | KEGG | Efficacy | Biomarker |
Busulfan | L01AB01 | D00248 | Antineoplastics | Philadelphia chromosome (BCR-ABL fusion gene) negative |
Rituximab | L01XC02 | D02994 | Antineoplastics | CD20 positive |
Trastuzumab | L01XC03 | D03257 | Antineoplastics | HER2 overexpression or gene amplification positive |
Cetuximab | L01XC06 | D03455 | Antineoplastics | EGFR expression positive KRAS exon 2 codon 12/13 mutation negative |
Panitumumab | L01XC08 | D05350 | Antineoplastics | EGFR expression positive KRAS exon 2 codon 12/13 mutation negative |
Ofatumumab | L01XC10 | D09314 | Antineoplastics | CD20 positive |
Brentuximab vedotin | L01XC12 | D09587 | Antineoplastics | CD30 positive |
Pertuzumab | L01XC13 | D05446 | Antineoplastics | HER2 overexpression positive |
Trastuzumab emtansine | L01XC14 | D09980 | Antineoplastics | HER2 overexpression or gene amplification positive |
Obinutuzumab | L01XC15 | D09321 | Antineoplastics | CD20 positive |
Dinutuximab | L01XC16 | D10559 | Antineoplastics | MYCN amplification positive |
Nivolumab | L01XC17 | D10316 | Antineoplastics | BRAF V600 mutation positive PD-L1 protein expression positive |
Pembrolizumab | L01XC18 | D10574 | Antineoplastics | BRAF V600 mutation positive PD-L1 protein expression positive |
Blinatumomab | L01XC19 | D09325 | Antineoplastics | Philadelphia chromosome (BCR-ABL fusion gene) negative |
Imatinib | L01XE01 | D01441 | Antineoplastics | Philadelphia chromosome (BCR-ABL fusion gene) positive FIP1L1-PDGFRA fusion gene positive KIT mutation D816V negative PDGFR rearrangement positive |
Gefitinib | L01XE02 | D01977 | Antineoplastics | EGFR exon 19 deletion or exon 21 L858R mutation positive |
Erlotinib | L01XE03 | D04023 | Antineoplastics | EGFR expression positive EGFR exon 19 deletion or exon 21 L858R mutation positive |
Dasatinib | L01XE06 | D06414 | Antineoplastics | Philadelphia chromosome positive, BCR-ABL T315I mutation positive |
Lapatinib | L01XE07 | D04024 | Antineoplastics | HER2 overexpression positive HLA-DQA1*0201 or HLA-DRB1*0701 allele carrier |
Nilotinib | L01XE08 | D08953 | Antineoplastics | Philadelphia chromosome (BCR-ABL fusion gene) positive UGT1A1*28 allele homozygotes |
Everolimus | L01XE10 L04AA18 |
D02714 | Antineoplastics | HER2 overexpression negative ESR1 positive |
Afatinib | L01XE13 | D09733 | Antineoplastics | EGFR exon 19 deletion or exon 21 L858R mutation positive |
Bosutinib | L01XE14 | D09728 | Antineoplastics | Philadelphia chromosome (BCR-ABL fusion gene) positive |
Vemurafenib | L01XE15 | D09996 | Antineoplastics | BRAF V600E mutation positive NRAS mutation positive |
Crizotinib | L01XE16 | D09731 | Antineoplastics | EML4-ALK gene rearrangement positive |
Dabrafenib | L01XE23 | D10104 | Antineoplastics | BRAF V600E mutation positive G6PD deficient |
Ponatinib | L01XE24 | D09951 | Antineoplastics | Philadelphia chromosome positive, BCR-ABL T315I mutation positive |
Trametinib | L01XE25 | D10176 | Antineoplastics | BRAF V600E/K mutation positive |
Cabozantinib | L01XE26 | D10095 | Antineoplastics | RET mutation positive |
Ibrutinib | L01XE27 | D10223 | Antineoplastics | Chromosome 17p deletion positive |
Ceritinib | L01XE28 | D10551 | Antineoplastics | ALK gene rearrangement positive |
Palbociclib | L01XE33 | D10372 | Antineoplastics | ESR1 positive HER2 overexpression negative |
Osimertinib | L01XE35 | D10766 | Antineoplastics | EGFR T790M mutation positive |
Alectinib | L01XE36 | D10450 | Antineoplastics | ALK gene rearrangement positive |
Cobimetinib | L01XE38 | D10615 | Antineoplastics | BRAF V600E/K mutation positive |
Tretinoin | L01XX14 | D00094 | Antineoplastics | PML-RARA translocation positive |
Arsenic trioxide | L01XX27 | D02106 | Antineoplastics | PML-RARA translocation positive |
Denileukin diftitox | L01XX29 | D03682 | Antineoplastics | CD25 positive |
Omacetaxine | L01XX40 | D08956 | Antineoplastics | Philadelphia chromosome (BCR-ABL fusion gene) negative |
Olaparib | L01XX46 | D09730 | Antineoplastics | BRCA1,2 mutation positive |
Belinostat | L01XX49 | D08870 | Antineoplastics | UGT1A1*28 allele homozygotes |
Venetoclax | L01XX52 | D10679 | Antineoplastics | Chromosome 17p deletion positive |
Tamoxifen | L02BA01 | D00966 | Antineoplastics | ESR1, PGR positive Factor V Leiden negative Prothrombin mutation negative |
Fulvestrant | L02BA03 | D01161 | Antineoplastics | ESR1, PGR positive |
Anastrozole | L02BG03 | D00960 | Antineoplastics | ESR1, PGR positive |
Letrozole | L02BG04 | D00964 | Antineoplastics | ESR1, PGR positive |
Exemestane | L02BG06 | D00963 | Antineoplastics | ESR1, PGR positive |
Tositumomab | V10XA53 | D08622 | Antineoplastics | CD20 positive |
Ibritumomab tiuxetan | V10XX02 | D04489 | Antineoplastics | CD20 positive |
Drug | ATC | KEGG | Efficacy | Biomarker |
Omeprazole | A02BC01 | D00455 D05259 |
Gastrointestinal agents; Proton pump inhibitors | CYP2C19 poor metabolizer |
Pantoprazole | A02BC02 | D02593 | Gastrointestinal agents; Proton pump inhibitors | CYP2C19 poor metabolizer |
Lansoprazole | A02BC03 | D00355 | Gastrointestinal agents; Proton pump inhibitors | CYP2C19 intermediate or poor metabolizer |
Rabeprazole | A02BC04 | D00724 | Gastrointestinal agents; Proton pump inhibitors | CYP2C19 poor metabolizer |
Esomeprazole | A02BC05 | D01984 D04056 D10120 |
Gastrointestinal agents; Proton pump inhibitors | CYP2C19 poor metabolizer |
Dexlansoprazole | A02BC06 | D08903 | Gastrointestinal agents; Proton pump inhibitors | CYP2C19 poor metabolizer |
Metoclopramide | A03FA01 | D05008 | Antiemetics | CYB5R1-4 deficient G6PD deficient |
Palonosetron | A04AA05 | D05343 | Anti-emetic, 5-HT3 receptor antagonist | CYP2D6 poor metabolizer |
Cholic acid | A05AA03 | D10699 | Choleretic | AKR1D1,HSD3B7,CYP27A1,AMACR,CYP7A1 deficient |
PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid | Osmotic laxatives | G6PD deficient | ||
Glibenclamide (Glyburide) | A10BB01 | D00336 | Antidiabetic agents | G6PD deficient |
Chlorpropamide | A10BB02 | D00271 | Antidiabetic agents | G6PD deficient |
Glipizide | A10BB07 | D00335 | Antidiabetic agents | G6PD deficient |
Glimepiride | A10BB12 | D00593 | Antidiabetic agents | G6PD deficient |
Carglumic acid | A16AA05 | D07130 | Antihyperammonemic | NAGS deficient |
Velaglucerase alfa | A16AB10 | D09029 | Gaucher disease treatment | GBA deficient |
Elosulfase | A16AB12 | D10333 | mucopolysaccharidosis IV treatment | GALNS deficient |
Sodium phenylbutyrate | A16AX03 | D05868 | Antihyperammonemic | CPS,OTC,NAGS /ASS,ASL /ARG deficient |
Eliglustat | A16AX10 | D09893 | Gaucher disease treatment | CYP2D6 ultrarapid, intermediate or poor metabolizer |
Sodium phenylacetate and sodium benzoate |
D10205 | Antihyperammonemic | CPS,OTC,NAGS /ASS,ASL /ARG deficient | |
Warfarin | B01AA03 | D00564 | Antithrombotic agents | VKORC1 rs9923231 allele carrier CYP2C9 intermediate or poor metabolizer PROS deficient PROC deficient |
Clopidogrel | B01AC04 | D00769 | Antithrombotic agents | CYP2C19 intermediate or poor metabolizers |
Prasugrel | B01AC22 | D05597 | Antithrombotic agents | CYP2C19 poor metabolizer CYP2C9 variant allele carrier CYP3A5 variant allele carrier CYP2B6 variant allele carrier |
Ticagrelor | B01AC24 | D09017 | Antithrombotic agents | CYP2C19 poor metabolizer |
Eltrombopag | B02BX05 | D03978 | Antihemorrhagics | Factor V Leiden carrier SERPINC1 deficient |
Quinidine | C01BA01 | D00642 D02272 |
Cardiovascular agents; Antiarrhythmics | CYP2D6 poor metabolizer |
Propafenone | C01BC03 | D00640 | Cardiovascular agents; Antiarrhythmics | CYP2D6 poor metabolizer |
Hydralazine and isosorbide | D10209 | Cardiovascular agents; Vasodilators | NAT1,2 slow acetylator | |
Propranolol | C07AA05 | D00483 | Cardiovascular agents; Beta blocking agents | CYP2D6 poor metabolizer |
Metoprolol | C07AB02 | D00601 D00635 |
Cardiovascular agents; Beta blocking agents | CYP2D6 poor metabolizer |
Carvedilol | C07AG02 | D00255 D03415 |
Cardiovascular agents; Beta blocking agents | CYP2D6 poor metabolizer |
Pravastatin | C10AA03 | D00893 | Cardiovascular agents; HMG-CoA reductase inhibitors | LDLR mutation heterozygotes and homozygotes |
Atorvastatin | C10AA05 | D00887 D02258 |
Cardiovascular agents; HMG-CoA reductase inhibitors | LDLR deficient |
Rosuvastatin | C10AA07 | D01915 | Cardiovascular agents; HMG-CoA reductase inhibitors | LDLR deficient |
Mipomersen | C10AX11 | D08946 | Antisense ApoB-100 mRNA | LDLR mutation heterozygotes and homozygotes |
Lomitapide | C10AX12 | D09638 | MTTP inhibitor | LDLR mutation homozygotes |
Evolocumab | C10AX13 | D10557 | Antihyperlipidemic | LDLR mutation heterozygotes and homozygotes |
Alirocumab | C10AX14 | D10335 | Antihyperlipidemic | LDLR mutation heterozygotes |
Terbinafine | D01AE15 D01BA02 |
D02219 | Antifungals | CYP2D6 poor metabolizer |
Mafenide | D06BA03 | D01166 | Antiinfectives | G6PD deficient |
Dapsone | D10AX05 J04BA02 |
D00592 | Antimycobacterials | G6PD deficient |
Drospirenone and ethinylestradiol | G03AA12 | D09741 | Hormonal agents | CYP2C19 intermediate metabolizer |
Tolterodine | G04BD07 | D01148 | Genitourinary agents | CYP2D6 poor metabolizer |
Fesoterodine | G04BD11 | D08923 | Genitourinary agents | CYP2D6 poor metabolizer |
Parathyroid hormone | H05AA03 | D05364 | Antihypocalcemia | CASR positive |
Sulfamethoxazole and trimethoprim | J01EE01 | D00285 | Antibacterials | G6PD deficient |
Nalidixic acid | J01MB02 | D00183 | Antibacterials | G6PD deficient |
Nitrofurantoin | J01XE01 | D00439 | Antibacterials | G6PD deficient |
Voriconazole | J02AC03 | D00578 | Antifungals | CYP2C19 intermediate or poor metabolizer |
Rifampin, isoniazid, and pyrazinamide | D10210 | Antiinfective | NAT1,2 slow acetylator | |
Telaprevir | J05AE11 | D09012 | Antivirals | IL28B SNP rs12979860 |
Boceprevir | J05AE12 | D08876 | Antivirals | IL28B SNP rs12979860 |
Simeprevir | J05AE14 | D10469 | Antivirals | IL28B SNP rs12979860 |
Sofosbuvir | J05AX15 | D10366 | Antivirals | IL28B SNP rs12979860 |
Abacavir | J05AF06 | D00891 | Antivirals | HLA-B polymorphism *5701 |
Dolutegravir | J05AX12 | D10113 | Antivirals | UGT1A1 poor metabolizer |
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir | J05AX66 | D10582 | Antivirals | IL28B SNP rs12979860 |
Mercaptopurine | L01BB02 | D00161 | Antineoplastics | TPMT polymorphism |
Thioguanine | L01BB03 | D06109 | Antineoplastics | TPMT polymorphism |
Fluorouracil | L01BC02 | D00584 | Antineoplastics | DPD deficient |
Capecitabine | L01BC06 | D01223 | Antineoplastics | DPD deficient |
Cisplatin | L01XA01 | D00275 | Antineoplastics | TPMT polymorphism |
Lapatinib | L01XE07 | D04024 | Antineoplastics | HLA-DQA1 polymorphism *0201 HLA-DRB1 polymorphism *0701 |
Pazopanib | L01XE11 | D05380 | Antineoplastics | UGT1A1*28 allele homozygotes |
Irinotecan | L01XX19 | D01061 | Antineoplastics | UGT1A1*28 allele carrier |
Peginterferon alfa-2b | L03AB10 | D02748 | Immunomodulator | IL28B SNP rs12979860 |
Mycophenolic acid | L04AA06 | D00752 D05095 D05096 |
Immunomodulator | HGPRT deficient |
Belimumab | L04AA26 | D03068 | Immunomodulator | ANA positive |
Azathioprine | L04AX01 | D00238 | Immunomodulator | TPMT polymorphism |
Lenalidomide | L04AX04 | D04687 | Antineoplastics | Chromosome 5q deletion |
Celecoxib | L01XX33 M01AH01 |
D00567 | Antiinflammatory (NSAID) | CYP2C9 polymorphism |
Flurbiprofen | M01AE09 M02AA19 R02AX01 S01BC04 |
D00330 D02290 |
Antiinflammatory (NSAID) | CYP2C9 polymorphism |
Carisoprodol | M03BA02 | D00768 | Muscle relaxants | CYP2C19 polymorphism |
Lesinurad | M04AB05 | D09921 | Antigout agents | CYP2C9 poor metabolizer |
Pegloticase | M04AX02 | D09316 | Antigout agents | G6PD deficient |
Sevoflurane | N01AB08 | D00547 | Anesthetic | RYR1 positive |
Prilocaine and lidocaine | N01BB52 N01BB54 |
D02740 | Anesthetics | CYBR1-4 deficient G6PD deficient |
Tramadol | N02AX02 | D01355 | Analgesics | CYP2D6 poor metabolizer |
Tramadol and acetaminophen | N02AX52 | D09999 | Analgesics | CYP2D6 poor metabolizer |
Phenytoin | N03AB02 | D00512 D02103 |
Antiepileptics | HLA-B polymorphism *1502 |
Carbamazepine | N03AF01 | D00252 | Antiepileptics | HLA-B polymorphism *1502 HLA-A polymorphism *3101 |
Valproic acid | N03AG01 | D00399 D00304 D00710 |
Antiepileptics | POLG deficient CPS,OTC,NAGS /ASS,ASL /ARG deficiency |
Lacosamide | N03AX18 | D07299 | Antiepileptics | CYP2C19 poor metabolizer |
Perphenazine | N05AB03 | D00503 | Antipsychotics | CYP2D6 poor metabolizer |
Thioridazine | N05AC02 | D00798 | Antipsychotics | CYP2D6 poor metabolizer |
Pimozide | N05AG02 | D00560 | Antipsychotics | CYP2D6 poor metabolizer |
Clozapine | N05AH02 | D00283 | Antipsychotics | CYP2D6 poor metabolizer |
Risperidone | N05AX08 | D00426 | Antipsychotics | CYP2D6 poor metabolizer |
Aripiprazole | N05AX12 | D01164 D10364 |
Antipsychotics | CYP2D6 poor metabolizer |
Brexpiprazole | N05AX13 | D10309 | Antipsychotics | CYP2D6 poor metabolizer |
Iloperidone | N05AX14 | D02666 | Antipsychotics | CYP2D6 poor metabolizer |
Diazepam | N05BA01 | D00293 | Anxiolytics | CYP2C19 polymorphism |
Clobazam | N05BA09 | D01253 | Anxiolytics | CYP2C19 polymorphism |
Desipramine | N06AA01 | D00812 | Antidepressants | CYP2D6 poor metabolizer |
Imipramine | N06AA02 | D00815 | Antidepressants | CYP2D6 poor metabolizer |
Clomipramine | N06AA04 | D00811 | Antidepressants | CYP2D6 poor metabolizer |
Amitriptyline | N06AA09 | D00809 | Antidepressants | CYP2D6 poor metabolizer |
Trimipramine | N06AA06 | D02408 | Antidepressants | CYP2D6 poor metabolizer |
Nortriptyline | N06AA10 | D00816 | Antidepressants | CYP2D6 poor metabolizer |
Protriptyline | N06AA11 | D00484 | Antidepressants | CYP2D6 poor metabolizer |
Doxepin | N06AA12 | D00814 | Antidepressants | CYP2C19 poor metabolizer CYP2D6 polymorphism |
Fluoxetine | N06AB03 | D00823 | Antidepressants (SSRI) | CYP2D6 poor metabolizer |
Citalopram | N06AB04 | D00822 | Antidepressants (SSRI) | CYP2C19 poor metabolizer CYP2D6 polymorphism |
Paroxetine | N06AB05 | D02260 D05374 D05375 |
Antidepressants (SSRI) | CYP2D6 poor metabolizer |
Fluvoxamine | N06AB08 | D00824 | Antidepressants (SSRI) | CYP2D6 poor metabolizer |
Escitalopram | N06AB10 | D02567 | Antidepressants (SSRI) | CYP2C19 poor metabolizer CYP2D6 poor metabolizer |
Nefazodone | N06AX06 | D00819 | Antidepressants | CYP2D6 poor metabolizer |
Venlafaxine | N06AX16 | D00821 | Antidepressants | CYP2D6 poor metabolizer |
Vortioxetine | N06AX26 | D10185 | Antidepressants | CYP2D6 poor metabolizer |
Chlordiazepoxide and amitriptyline | N06CA01 | D10207 | Antidepressants | CYP2D6 poor metabolizer |
Modafinil | N06BA07 | D01832 | Antipsychotics | CYP2D6 poor metabolizer |
Atomoxetine | N06BA09 | D02574 | Antipsychotics | CYP2D6 poor metabolizer |
Galantamine | N06DA04 | D02173 | Antidementia | CYP2D6 poor metabolizer |
Cevimeline | N07AX03 | D00661 | Sjögren's syndrome dry-mouth treatment | CYP2D6 poor metabolizer |
Tetrabenazine | N07XX06 | D08575 | Huntington's disease chorea treatment | CYP2D6 poor metabolizer |
Dextromethorphan and quinidine | N07XX59 | D10208 | Pseudobulbar affect (PBA) treatment | CYP2D6 poor metabolizer |
Chloroquine | P01BA01 | D02125 | Antiparasitics | G6PD deficient |
Primaquine | P01BA03 | D02126 | Antiparasitics | G6PD deficient |
Quinine sulfate | P01BC01 | D02262 | Antiparasitics | G6PD deficient CYP2D6 poor metabolizer |
Indacaterol | R03AC18 | D09319 | Chronic obstructive pulmonary disease (COPD) treatment | UGT1A1 polymorphism *28 |
Arformoterol | D02981 | Chronic obstructive pulmonary disease (COPD) treatment | UGT1A1 poor metabolizer CYP2D6 intermediate or poor metabolizer |
|
Codeine | R05DA04 | D03580 | Analgesics | CYP2D6 poor metabolizer |
Ivacaftor | R07AX02 | D09916 | Cystic fibrosis treatment | CFTR mutation (G551D) |
Lumacaftor and ivacaftor | R07AX30 | D10685 | Cystic fibrosis treatment | CFTR mutation (F508del) |
Sodium nitrite | V03AB08 | D05865 | Antidotes | G6PD deficient |
Methylene blue | V03AB17 | D02312 | Antidotes | G6PD deficient |
Succimer | D00572 | Electrolytes | G6PD deficient | |
Rasburicase | V03AF07 | D05704 | Antihyperuricemics | G6PD deficient CYB5R1-4 deficiency |